- Home
- CSAN vs ACLX Comparison
CSAN vs ACLX Comparison
Compare CSAN & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSAN | ACLX |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2008 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CSAN | ACLX |
|---|---|---|
| Price | $4.96 | $113.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 15 |
| Target Price | $4.75 | ★ $115.85 |
| AVG Volume (30 Days) | 1.9M | ★ 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $270.73 | N/A |
| Revenue Next Year | $2.12 | $286.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.72 | $47.86 |
| 52 Week High | $6.25 | $114.26 |
Technical Indicators
Market Signals| Indicator | CSAN | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 83.54 |
| Support Level | $4.36 | $64.61 |
| Resistance Level | $5.23 | N/A |
| Average True Range (ATR) | 0.24 | 1.96 |
| MACD | 0.02 | 5.33 |
| Stochastic Oscillator | 49.73 | 99.00 |
Price Performance
Historical ComparisonAbout CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.